SINOPHARM GROUP 1/5/O.N. (X2S1) — Capital Reinvestment Ratio
SINOPHARM GROUP 1/5/O.N. (X2S1) has a Capital Reinvestment Ratio of 0.11x as of December 2025, meaning it reinvests 0% of its operating cash flow (€14.14 Billion) in capital expenditures (€1.62 Billion). Check tangible equity quality of SINOPHARM GROUP 1/5/O.N. to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
SINOPHARM GROUP 1/5/O.N. Capital Reinvestment Ratio (2021–2025)
This chart tracks SINOPHARM GROUP 1/5/O.N.'s Capital Reinvestment Ratio across 5 annual periods. For the full cash flow conversion analysis, see X2S1 cash flow metrics.
Annual Capital Reinvestment Ratio for SINOPHARM GROUP 1/5/O.N. (2021–2025)
Year-by-year Capital Reinvestment Ratio for SINOPHARM GROUP 1/5/O.N. from 2021 to 2025. See X2S1 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.11x | €14.14 Billion | €1.62 Billion | ▼ -32.9% |
| 2024 | 0.17x | €11.55 Billion | €1.97 Billion | ▲ +25.3% |
| 2023 | 0.14x | €17.17 Billion | €2.34 Billion | ▲ +17.9% |
| 2022 | 0.12x | €20.96 Billion | €2.42 Billion | ▼ -52.4% |
| 2021 | 0.24x | €9.31 Billion | €2.26 Billion | — |